Literature DB >> 29484391

Melatonin attenuated inflammatory reaction by inhibiting the activation of p38 and NF‑κB in taurocholate‑induced acute pancreatitis.

Yina Chen1, Qian Zhao2, Qinfen Chen2, Yuxue Zhang3, Bule Shao4, Yin Jin2, Jiansheng Wu2.   

Abstract

The aim of the present study was to investigate the protective mechanism underlying of melatonin in severe acute pancreatitis (SAP). A total of 64 male Sprague‑Dawley rats were randomly divided into four groups: The sham operation (SO) group, SAP group, melatonin treatment (MLT) group and p38 inhibitor (SB203580) treatment (SB) group. Acute pancreatitis was induced by 5% taurocholate through retrograde infusion into the biliopancreatic ducts. The melatonin and SB203580 treatment groups were administered with MLT and SB 30 min before operation the induction of SAP. Rats in each group were euthanized at 6 and 12 h following SAP induction. Blood and pancreatic tissues were removed for inflammatory examination. Peripheral blood mononuclear cells (PBMCs) were isolated following sacrifice to measure the phosphorylation of p38 and nuclear factor‑κB (NF‑κB was measured as p65 and phosphorylation of p65). The pretreatment of melatonin significantly attenuated the severity of pancreatitis. In addition, melatonin also reduced serum amylase and proinflammatory cytokine levels, including tumor necrosis factor‑α, interleukin (IL)‑1 and IL‑6. The mean pathological scores for pancreatic tissues in the MLT group were higher than those for samples in the SO group, but were lower than those for samples in the SAP group at each time-point. Phosphorylation of p38 and p65 levels in the melatonin treatment group were lower than that in the SAP group, and higher in the SAP group than in the SO group, and the SB203580 treatment group. Furthermore, melatonin significantly inhibited the activation of p38 and NF‑κB in PBMCs. The authors revealed that melatonin may attenuate inflammatory reactions by inhibiting the activation of p38 MAPK and NF‑κB in both acute pancreatitis rats and PBMCs. SAP is a severe disease with a high risk of morbidity and mortality. It is important to attenuated inflammatory reaction in acute pancreatitis. Thus, the authors studied melatonin, which is synthesized by the pineal gland and released into the blood. Previous studies have shown that melatonin serves a protective role in the early course of human acute pancreatitis, and melatonin concentration variations are closely related to the severity of acute pancreatitis. It may be concluded that melatonin may attenuates inflammatory reactions by inhibiting the activation of p38 MAPK and NF‑κB in both acute pancreatitis rats and PBMCs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29484391     DOI: 10.3892/mmr.2018.8614

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Anti-Inflammatory Effects of Melatonin in Rats with Induced Type 2 Diabetes Mellitus.

Authors:  Hande Yapislar; Ebru Haciosmanoglu; Turkan Sarioglu; Sevgin Degirmencioglu; Ibrahim Sogut; Michael Poteser; Cem Ekmekcioglu
Journal:  Life (Basel)       Date:  2022-04-12

2.  PSD-95 protects the pancreas against pathological damage through p38 MAPK signaling pathway in acute pancreatitis.

Authors:  Yinan Guo; Weikai Hu; Xueyan Wang; Chunyun Li; Tianyu Cui; Ruixia Liu; Junqi He; Chenghong Yin
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

Review 3.  Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders; A Review of Clinical Evidences.

Authors:  Saeed Abdi; Mohammad Abbasinazari; Sara Ataei; Neda Khanzadeh-Moghaddam; Negin Keshvari
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

4.  Dexamethasone inhibits NF‑кBp65 and HMGB1 expression in the pancreas of rats with severe acute pancreatitis.

Authors:  Shangping Zhao; Jinming Yang; Ting Liu; Juanxian Zeng; Liangliang Mi; Kaimin Xiang
Journal:  Mol Med Rep       Date:  2018-10-25       Impact factor: 2.952

5.  Drug discovery and formulation development for acute pancreatitis.

Authors:  Xue Jiang; Ya-Wen Zheng; Shihui Bao; Hailin Zhang; Ruijie Chen; Qing Yao; Longfa Kou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.